Evidence map›Paper›PMID 42870834›Full record

ArticleTranslational lung cancer research2026

Efficacy and safety of third-generation

Jiajie Sun, Xinjing Li, Bingxue Wang, Zhangxuan Chen, Yang Yao, Ranpu Wu, Xiaohua Pan, Xuanhao Xu, Yunxiao Si, Hongbing Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiajie SunDepartment of Respiratory and Critical Care Medicine, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China.
Xinjing LiDepartment of Respiratory and Critical Care Medicine, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Bingxue WangDepartment of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Zhangxuan ChenDepartment of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Yang YaoDepartment of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Ranpu WuDepartment of Respiratory and Critical Care Medicine, Jinling Hospital, Southeast University School of Medicine, Nanjing, China.
Xiaohua PanSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Xuanhao XuDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yunxiao SiDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hongbing LiuDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Third-generation epidermal growth factor receptor ( Methods: We retrospectively analyzed 29 patients with advanced Results: The median number of prior systemic treatment lines was 5 (range, 3-12). Third-generation Conclusions: Third-generation EGFR-TKI rechallenge may provide a feasible and well-tolerated salvage option for selected heavily pretreated patients with

Indexed as

EGFR tyrosine kinase inhibitors (EGFR TKIs)Non-small cell lung cancer (NSCLC)rechallenge therapytargeted therapy

Identifiers

PMID42870834
PMCPMC13657885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.